Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27

Outlook Therapeutics, Inc.

2025-Q2 EPS reported -$1.05 vs consensus -$0.40 ▼ miss (-161.7%)

Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).
Cash and equivalents $7.6M as of March 31, 2025; no revenue (pre-commercial stage).
LYTENAVA commercial launch in Germany and UK planned for Q2 CY2025.
FDA PDUFA goal date August 27, 2025 for ONS-5010 (bevacizumab-vikg) BLA resubmission.
Warrant inducement expenses $33.9M and other non-cash items drove adjusted loss items.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-049411
form_type: 8-K
ticker: OTLK
cik: 0001649989
company_name: Outlook Therapeutics, Inc.
filed_at: 2025-05-15T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.197278+00:00
generated_at: 2026-05-21T05:14:52.848496+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-049411
json_url: https://secwatch.observer/filing/0001104659-25-049411.json
markdown_url: https://secwatch.observer/filing/0001104659-25-049411.md
text_url: https://secwatch.observer/filing/0001104659-25-049411.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/0001104659-25-049411-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-049411

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.